CYP2D6 and CYP3A4 double transgenic mice
University at Buffalo - The State University of New York
posted on 10/20/2009
Human CYP2D6 and CYP3A4 collectively metabolize over 70% of drugs on the market. In an effort to study the developmental and sexual expression and regulation of these two major human drug-metabolizing P450s, a double transgenic mouse line carrying both CYP2D6 and CYP3A4 transgenes (Tg-CYP2D6/CYP3A4) was generated by a pharmaceutical scientist at the University at Buffalo in collaboration with researchers at the National Cancer Institute. The CYP2D6/CYP3A4 double transgenic mouse model could provide insight into potential differences in CYP expression and induction and effects on drug-drug interactions (DDIs) between men and women. This mouse model could serve as a useful tool for preclinical drug development The mice and/or tissue samples are available for purchase and licensing. Additional information can be found in DMD 36:435-441, 2008.
Detailed Description
File Number: 6323
Other Information: Principal Investigator: Aiming Yu
This innovation currently is not available for online licensing. Please contact Tim Dee at University at Buffalo - The State University of New York for more information.
Find more innovations
